Cardiff Oncology Inc Discusses KRAS Mutations in Cancer Transcript
Welcome to TrialSite News podcast series. Today we are pleased to welcome Mark Erlander, Chief Executive Officer at Cardiff Oncology, Inc. Now Cardiff Oncology, Inc. is a clinical-stage biotechnology company with a singular mission of developing new treatment options for cancer patients in indications with the greatest medical need.
So Mark, thank you for joining our podcast today. We are honored to have you on the show.
Well, likewise, I'm also honored to be here, and thank you all for taking time out of your life to listen to this podcast. I really would like to talk to you about Cardiff Oncology and what we're doing here, and our passion for cancer patients, and what we're -- how we're doing that, and our involvement in various clinical trials with a drug that we have, that we think has a lot of promise, particularly for colorectal cancer patients as well as other cancer patients. So thank you for this opportunity.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
